IKZF1 and acute myeloid leukemia: Notably, immunomodulatory drugs inducing IKAROS protein degradation showed potential therapeutic efficiency in the HOXA‐related AML, which suggests the emerging synergistic role of IKAROS in high‐risk AML.27